← Back to Search

Monoclonal Antibodies

DSC-MRI for Recurrent Glioblastoma

Led By Jerrold Boxerman
Research Sponsored by ECOG-ACRIN Cancer Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically proven intracranial glioblastoma or gliosarcoma at initial surgery
Patients able to withstand 22 gauge intravenous (IV) placement
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Study Summary

This trial uses DSC-MRI to measure rCBV to determine response to bevacizumab in patients with recurrent glioblastoma. DSC-MRI may help to evaluate changes in cancer blood vessels.

Who is the study for?
This trial is for adults with recurrent glioblastoma who can undergo MRI scans and have not been treated with immunotherapies. They must have a Karnofsky performance status of at least 70, no severe allergies to gadolinium, no MR-incompatible implants, and adequate organ function. Pregnant or breastfeeding women are excluded.Check my eligibility
What is being tested?
The study tests how well DSC-MRI measures blood volume changes in the brain as an early indicator of response to Bevacizumab treatment in patients experiencing their first recurrence of glioblastoma.See study design
What are the potential side effects?
While this trial focuses on imaging rather than drug effects, Bevacizumab may cause headaches, high blood pressure, bleeding problems, tiredness, and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My initial surgery confirmed I have glioblastoma or gliosarcoma.
I can have a small needle placed in my vein for treatment.
I can safely receive IV contrast.
My kidneys work well (eGFR >= 40).
I have never received immunotherapy treatments.
I am able to care for myself but may not be able to do active work.
I am not pregnant or breastfeeding.
I am scheduled for treatment with a standard dose of bevacizumab.
My low-grade brain tumor has transformed into a high-grade tumor.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in rCBV within enhancing tumor
Secondary outcome measures
Change in CBF
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (DSC-MRI)Experimental Treatment1 Intervention
Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.
First Studied
Drug Approval Stage
How many patients have taken this drug
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Completed Early Phase 1

Find a Location

Who is running the clinical trial?

ECOG-ACRIN Cancer Research GroupLead Sponsor
114 Previous Clinical Trials
175,916 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,586 Previous Clinical Trials
41,241,840 Total Patients Enrolled
314 Trials studying Glioblastoma
22,638 Patients Enrolled for Glioblastoma
Jerrold BoxermanPrincipal InvestigatorECOG-ACRIN Cancer Research Group

Media Library

Bevacizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03115333 — N/A
Glioblastoma Research Study Groups: Diagnostic (DSC-MRI)
Glioblastoma Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT03115333 — N/A
Bevacizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03115333 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are being enrolled in the study?

"For the successful completion of this clinical trial, 146 volunteers who match the pre-set inclusion criteria must join. The medical research is being carried out in various places including Washington University School of Medicine in Saint Louis, Arizona and Saint Joseph's Hospital and Medical Center in Phoenix, California."

Answered by AI

Are there still openings for participants in this investigation?

"Clinicaltrials.gov affirms that recruitment for this trial is currently underway, with the initial posting taking place on April 14th 2017 and a subsequent update being made June 8th 2022."

Answered by AI

Are there various sites conducting this scientific experiment in the same state?

"This trial is being conducted in conjunction with Washington University School of Medicine (St. Louis, MO), Saint Joseph's Hospital and Medical Center (Phoenix, AZ), Loma Linda University Medical Centre (Loma Linda, CA) as well as 47 other sites nationwide."

Answered by AI
~22 spots leftby May 2025